Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052400 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Charles Drew University of Medicine and Science.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03052400 is a Phase 2 study that was terminated before completion, run by Charles Drew University of Medicine and Science. The registered enrollment target is 8 participants.
The verdict
NCT03052400, a Phase 2 study, was terminated before completion, sponsored by Charles Drew University of Medicine and Science.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome
Interventions
- DRUG Placebo
- DRUG Mifepristone 600 mg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2021-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03052400
The ClinicalTrials.gov registry entry for NCT03052400 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03052400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03052400 about?
NCT03052400 is a clinical study titled "Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus". Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome
What is the current status of trial NCT03052400?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2017-02-03. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT03052400?
The interventions under investigation include: Placebo (DRUG), Mifepristone 600 mg daily (DRUG).
Who is sponsoring clinical trial NCT03052400?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.